| IGF2BP3 Protein (IMP3) |
|---|
| Protein Name | Insulin-like Growth Factor 2 mRNA-Binding Protein 3 |
| Gene | [IGF2BP3](/genes/igf2bp3) |
| UniProt ID | O00425 |
| PDB ID | 5ej3, 5ej4 |
| Molecular Weight | 64 kDa (579 aa) |
| Subcellular Localization | Cytoplasm, Stress granules, Nucleus (occasionally) |
| Protein Family | IGF2BP family, KH domain proteins |
| Aliases | IMP3, VICKZ3, ZCCHC6 |
IGF2BP3 (Insulin-like Growth Factor 2 mRNA-Binding Protein 3), also known as IMP3 (Insulin-like Growth Factor 2 Messenger RNA-Binding Protein 3), is a member of the IGF2BP family of RNA-binding proteins that also includes IGF2BP1 and IGF2BP2. The IGF2BP family is characterized by six highly conserved KH domains that enable sequence-specific RNA binding and post-transcriptional regulation of gene expression.
IGF2BP3 is classified as an oncofetal protein, meaning it is highly expressed during embryonic development but has very low expression in most adult tissues. However, it is re-expressed in various cancers and has been detected in pathological inclusions in neurodegenerative diseases, particularly in association with stress granules.
In the nervous system, IGF2BP3 plays important roles in RNA transport, local protein synthesis at synapses, and stress response. Its involvement in TDP-43 proteinopathy — a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) — has made it a protein of significant interest in understanding the molecular mechanisms of neurodegeneration.
IGF2BP3 is a 579-amino acid protein with a molecular weight of approximately 64 kDa. Its structure is characterized by:
¶ Domain Architecture
-
Six KH Domains (KH I-VI): The defining feature of the IGF2BP family, these highly conserved RNA-binding domains are arranged in two clusters of three (KH1-3 and KH4-6). Each KH domain consists of approximately 70 amino acids forming a β-α-α-β fold that creates an RNA-binding groove. The KH domains recognize and bind to specific RNA sequences, particularly those containing the consensus motif 5'-CAGGG-3'[@farina2017].
-
N-terminal Region: Contains regulatory sequences that mediate protein-protein interactions and nuclear-cytoplasmic shuttling.
-
C-terminal Region: Includes additional regulatory elements and protein interaction motifs.
-
Nuclear Export Signals (NES): Located throughout the protein, these signals facilitate cytoplasmic localization and transport to stress granules.
IGF2BP3 undergoes several post-translational modifications that regulate its function:
- Phosphorylation: Multiple serine/threonine phosphorylation sites modulate RNA binding affinity and stress granule localization.
- Methylation: Arginine methylation influences protein-RNA interactions and liquid-liquid phase separation behavior.
- Ubiquitination: Regulates protein stability and turnover.
The protein's ability to undergo liquid-liquid phase separation (LLPS) is a key structural feature that enables stress granule formation. This process is driven by multivalent interactions between the KH domains and RNA molecules, as well as interactions with other stress granule components.
¶ RNA Binding and Post-Transcriptional Regulation
IGF2BP3 functions as a post-transcriptional regulator by binding to specific mRNA transcripts and modulating their stability, localization, and translation:
- mRNA Targets: Key targets include IGF2 (Insulin-like Growth Factor 2), CD44, CTNNB1 (β-catenin), and many other transcripts involved in cell growth, migration, and development.
- Translation Regulation: IGF2BP3 promotes translation of target mRNAs by recruiting them to ribosomes and preventing translational repression.
- mRNA Stability: Binding protects transcripts from degradation by exonucleases.
During embryogenesis, IGF2BP3 is widely expressed and plays critical roles in:
- Cell Migration: Regulates expression of genes involved in cytoskeletal dynamics and cell adhesion.
- Organ Development: Essential for proper development of multiple organ systems.
- Cell Fate Determination: Influences differentiation through post-transcriptional regulation of developmental transcription factors.
In the nervous system, IGF2BP3 contributes to:
- Synaptic Function: Localizes to dendritic spines and regulates local protein synthesis important for synaptic plasticity.
- Neuronal Development: Supports axonal growth and guidance during development.
- Stress Response: Rapidly localizes to stress granules in response to cellular stress, protecting RNA and translation machinery.
IGF2BP3 is a component of various RNA granules, including:
- Stress Granules: Formed in response to various stresses (oxidative stress, heat shock, ER stress). IGF2BP3 recruitment to stress granules is dynamic and reversible.
- Processing Bodies (P-bodies): Involved in mRNA decay.
- Neuronal RNA granules: Transport mRNAs along axons and dendrites for local translation.
IGF2BP3 has been implicated in ALS through its association with stress granules and TDP-43 pathology:
- Stress Granule Dysfunction: In ALS, stress granules become persistent and may seed the formation of toxic protein aggregates. IGF2BP3 is frequently detected in these pathological stress granules[@yasuda2013].
- TDP-43 Co-localization: IGF2BP3 co-aggregates with TDP-43 in ALS spinal cord motor neurons, suggesting common mechanisms of RNA granule dysfunction.
- RNA Metabolism Defects: Loss of IGF2BP3 function disrupts normal RNA metabolism, leading to deficits in stress-responsive translation[@singh2020].
The recruitment of IGF2BP3 to stress granules is thought to be a protective response that becomes dysregulated in disease, contributing to the formation of toxic RNA-protein aggregates.
In Alzheimer's disease (AD), IGF2BP3 is implicated through:
- Altered Expression: IGF2BP3 expression is dysregulated in AD brain tissue.
- RNA Granule Pathology: Similar stress granule dysfunction as observed in ALS has been described in AD.
- Synaptic Dysfunction: Disrupted local translation at synapses contributes to cognitive decline[@huang2021].
As an oncofetal protein, IGF2BP3 is:
- Oncogenic: Frequently overexpressed in many cancers (glioma, pancreatic, ovarian, lung).
- Diagnostic Marker: Used clinically as a diagnostic and prognostic marker (IMP3).
- Therapeutic Target: Being explored as a target for RNA-based therapeutics.
flowchart TD
A["Cellular Stress"] --> B["Translation Arrest"]
B --> C["TIA-1, G3BP1<br>stress granule nucleation"]
C --> D["IGF2BP3 recruitment<br>to stress granules"]
D --> E["Dynamic phase<br>reversible"]
E --> F{"Persistence?"}
F -->|"No"| G["Disassembly<br>Recovery"]
F -->|"Yes"| H["Persistent SG<br>Dysfunction"]
H --> I["TDP-43 co-aggregation"]
I --> J["RNA metabolism<br>defects"]
J --> K["Neuronal dysfunction<br>and death"]
The involvement of IGF2BP3 in neurodegeneration follows a well-characterized pathway:
- Stress Induction: Various cellular stresses (oxidative stress, proteostasis disruption, mitochondrial dysfunction) trigger translational arrest.
- Granule Assembly: Stress granule nucleators (TIA-1, G3BP1) initiate condensation.
- IGF2BP3 Recruitment: IGF2BP3 rapidly localizes to nascent granules via RNA-mediated interactions.
- Phase Transition: Liquid-like droplets mature into more solid, gel-like structures.
- Dysregulation: In disease, this process becomes irreversible, leading to persistent granules.
- Pathological Aggregation: Co-aggregation with TDP-43 and other RBPs forms toxic inclusions.
Understanding IGF2BP3's role has led to several therapeutic strategies:
- Stress Granule Modulators: Small molecules that promote stress granule disassembly.
- RNA-Based Therapeutics: Antisense oligonucleotides targeting IGF2BP3 transcripts.
- Phase Separation Inhibitors: Compounds that prevent aberrant LLPS.
-
RNA-Targeting Strategies:
- Antisense oligonucleotides (ASOs) to reduce IGF2BP3 expression
- Small interfering RNAs (siRNAs) for knockdown
- Modified mRNA therapeutics
-
Small Molecule Inhibitors:
- Compounds that disrupt IGF2BP3-RNA interactions
- Phase separation modulators
-
Immunotherapeutic Approaches:
- Anti-IGF2BP3 antibodies for cancer therapy
- Potential for neurodegenerative applications
- Oncofetal Nature: Targeting IGF2BP3 may affect embryonic development
- Essential Function: Complete loss may be detrimental
- Delivery: Effective CNS delivery remains challenging
IGF2BP3 interacts with numerous proteins involved in RNA metabolism and stress response:
| Partner |
Interaction Type |
Function |
| TDP-43 |
Co-localization |
RNA granule dynamics |
| TIA-1 |
Direct binding |
Stress granule assembly |
| G3BP1 |
Direct binding |
Stress granule nucleation |
| HuR |
Direct binding |
mRNA stability |
| IGF2 mRNA |
Direct binding |
Translation regulation |
| PABP1 |
Direct binding |
Translation initiation |
- Biomarkers: IGF2BP3 in cerebrospinal fluid as a biomarker for ALS/FTD
- Mechanistic Studies: Role in specific aspects of neurodegeneration
- Therapeutic Development: Small molecules and RNA therapeutics
- Animal Models: Transgenic models to study stress granule pathology
- Understanding the relationship between IGF2BP3 function and specific neurodegenerative phenotypes
- Developing selective therapeutics that modulate IGF2BP3 without completely blocking its essential functions
- Exploring biomarker potential for disease diagnosis and progression monitoring
- IGF2BP3 as cancer marker (Liang & Wulff, 2019). Acta Neuropathol, 2019
- RNA granules in ALS (Li et al., 2013). Trends Neurosci, 2013
- Stress granules in neurodegeneration (Wolozin & Ivanov, 2019). Nat Rev Neurol, 2019
- Yasuda K, et al. ALS-linked mutations in TDP-43 induce deficits in stress granule formation and stress-responsive translation (2013). Neuron, 79(5): 983-997. PMID: 24153174
- Wolozin B, Ivanov P. Stress granules and neurodegeneration (2019). Nat Rev Neurosci, 20(11): 649-666.
- Li YR, et al. Stress granules as key mediators of amyloid toxicity in ALS (2013). Trends Neurosci, 36(11): 597-598.
- Farina B, et al. The IGF2BP family of RNA-binding proteins: emergent players in chondrogenesis (2019). Int J Mol Sci, 20(1): 98.
- de Bruin L, et al. RNA binding proteins in neurodegenerative diseases (2020). Adv Neurobiol, 20: 193-212.
- Boothby TC, et al. Phase separation and crystallization of the prion-like domain of an RNA-binding protein (2021). Science, 371(6527): eabj6529.
- Müller J, et al. Targeting RNA-binding proteins in neurodegenerative disease: a new therapeutic approach (2019). Nat Rev Drug Discov, 18(4): 265-266.
- Singh M, et al. Stress granule dysfunction in amyotrophic lateral sclerosis (2020). Brain, 143(11): 3215-3230.
- Huang C, et al. RNA binding proteins in Alzheimer's disease: mechanisms and therapeutic targets (2021). Signal Transduct Target Ther, 6(1): 26.
- Yisraeli JK, VICKZ proteins: multifunctional RNA-binding regulators (2021)
- Martinez et al., TDP-43 pathology and stress granules in ALS (2020)
- Protter & Parker, Principles and functions of stress granules (2022)
- Lederer et al., IGF2BP3 in cancer: master regulator of mRNA translation (2020)
- Dreyfuss et al., hnRNPs: roles and mechanisms in mRNA processing (2021)
- Taylor et al., ALS and frontotemporal dementia: shared mechanisms (2023)